Background Gastric carcinoma (GC) has one of the highest mortality rates of cancer diseases and has a high incidence rate in China. Palliative chemotherapy is the main treatment for advanced gastric cancer. It is necessary to compare the effectiveness and toxicities of different regimens. This study explores the possibility of methylation of DNA damage repair genes serving as a prognostic and chemo-sensitive marker in human gastric cancer. Methods The methylation status of five DNA damage repair genes (CHFR, FANCF, MGMT, MLH1, and RASSF1A) was detected by nested methylation-specific PCR in 102 paraffin-embedded gastric cancer samples. Chi-square or Fisher's exact tests were used to evaluate the association of methylation status and clinic-pathological factors. The Kaplan-Meier method and Cox proportional hazards models were employed to analyze the association of methylation status and chemo-sensitivity. Results The results indicate that CHFR, MLH1, RASSF1A, MGMT, and FANCF were methylated in 34.3 % (35/102), 21.6 % (22/102), 12.7 % (13/102), 9.8 % (10/102), and 0 % (0/102) of samples, respectively. No association was found between methylation of CHFR, MLH1, RASSF1A, MGMT, or FANCF with gender, age, tumor size, tumor differentiation, lymph node metastasis, and TNM stage. In docetaxel-treated gastric cancer patients, resistance to docetaxel was found in CHFR unmethylated patients by Cox proportional hazards model (HR 0.243, 95 % CI, 0.069-0.859, p = 0.028), and overall survival is longer in the CHFR methylated group compared with the CHFR unmethylated group (log-rank, p = 0.036). In oxaliplatin-treated gastric cancer patients, resistance to oxaliplatin was found in MLH1 methylated patients (HR 2.988, 95 % CI,, p = 0.038), and overall survival was longer in the MLH1 unmethylated group compared with the MLH1 methylated group (log-rank, p = 0.046). Conclusions CHFR is frequently methylated in human gastric cancer, and CHFR methylation may serve as a docetaxel-sensitive marker. MLH1 methylation was related to oxaliplatin resistance in gastric cancer patients.
Introduction
Gastric cancer is the fourth most commonly diagnosed cancer and the second leading cause of cancer-related death worldwide, with the highest incidence in Eastern Asian countries [1] . Most patients are diagnosed at an advanced stage, and chemotherapy becomes an important approach. However, prognosis remains unsatisfactory because of side effects and chemo-resistance. It is desirable to find a group of chemo-sensitive markers.
Methylation of the DNA damage repair gene was reported as a chemo-sensitive markers in a few cancers. To find chemo-sensitive markers in gastric cancer, we analyzed five DNA damage repair genes in this study.
Checkpoint with FHA and ring finger (CHFR) is a G2/ M checkpoint inhibitor. Methylation of CHFR was reported to be sensitive to paclitaxel in endometrial and gastric cancer cell lines [2, 3] . The RAS association domain family 1A (RASSF1A) gene, a candidate tumor suppressor, may regulate microtubule and genomic stability [4] . RASSF1A hypermethylation mediated resistance to cisplatin and tamoxifen in male germ cell tumors and breast cancer [5, 6] . FANCF is a member of the Fanconi anemia gene family. Recently, it has been shown that promoter region hypermethylation disrupts the FA-BRCA pathway, resulting in cisplatin resistance in other malignant tumors [7, 8] . O 6 -Methylguanin DNA methyltransferase (MGMT) removes mutagenic alkyl groups from the O 6 position of guanine, leading to G?A transitions after DNA damage [9] . MGMT is frequently lost because of methylation in brain tumors, and this methylation correlates with responsiveness to alkylator-based chemotherapy [10] [11] [12] . Demethylation of MLH1 (mutL homologue 1), a DNA mismatch repair gene, sensitizes the A2780 cell line to platinum [13] . In this study, we mainly focused on the methylation status of these five DNA repair genes and the sensitivity of oxaliplatin and docetaxel in gastric cancer.
Methods

Gastric cancer samples
We 
DNA preparation
Paraffin-embedded samples were sliced to 8 lm and deparaffinized by xylene. DNA was prepared by the proteinase K method. DNA samples were stored at -20°C in low TE buffer.
Nested methylation-specific polymerase chain reaction (PCR)
Nested PCR was performed to facilitate the examination of the methylation of CHFR, MLH1, MGMT, RASSF1A and FANCF on paraffin-embedded gastric cancer samples. The bisulfite-modified DNA was subjected to a first-stage PCR incorporating external primer sets. The PCR reaction was carried out in a total volume of 25 ll with 1 U Taq Polymerase (Invitrogen, Carlsbad, CA, USA), 25 pmol external primer, 100 pmol dNTPs, 2.5 ll 109 PCR buffer, and 2 ll bisulfite-modified DNA. External primer sequences are shown in Table 1 . PCR conditions included an initial denaturation at 95°C for 5 min, followed by 35 cycles of amplification (95°C 9 30 s, 55°C 9 30 s, 72°C 9 40 s), and a final elongation step at 72°C for 5 min. PCR products were analyzed on a 2 % agarose gel to confirm adequate template for subsequent second-stage internal methylation-specific PCR (MSP).
Methylation-specific PCR MSP primers were designed according to genomic sequences flanking the presumed transcriptional start sites. Primer sequences were oligo-synthesized (Invitrogen) to detect bisulfite-induced changes affecting unmethylated (U) and methylated (M) alleles. The MSP of 5 genes was carried out using primers showed in Table 1 . A 1:1,000 dilution of external PCR product was used as internal MSP template. For each reaction, 2 ll diluted external PCR product was added. The composition of the PCR reaction is as same as the external PCR. Cycle conditions were 95°C 9 5 min for 1 cycle; 28 cycles 9 (95°C 9 30 s, 60°C 9 30 s, 72°C 9 30 s); and 72°C 9 5 min for 1 cycle. Each PCR assay included a positive control, using DNA treated in vitro with SssI methyltransferase (New England Biolabs, Ipswich, MA, USA). MSP products were analyzed using 2 % agarose gel electrophoresis.
Statistical analysis
Statistical analysis was performed using SPSS 16.0 software (SPSS, Chicago, IL, USA). Chi-square or Fisher's exact tests were used to evaluate the relationship between methylation status and clinicopathological characteristics. Survival rates were calculated by the Kaplan-Meier method, and differences in survival curve were evaluated using the log-rank test. Cox proportional hazards models were fit to determine independent associations of CHFR or MLH1 methylation with overall survival outcome. Twosided tests were used to determine significance, and p \ 0.05 was considered statistically significant.
Results
Methylation status of DNA repair genes and the association of methylation with clinicopathological features in gastric cancer
Methylation status of CHFR, FANCF, MGMT, MLH1, and RASSF1A was examined by MSP in 102 cases of human primary gastric cancer. No methylation was found in the FANCF gene; 35 cases (34.4 %) were methylated in the CHFR gene, 22 cases (21.6 %) were methylated in the MLH1 gene, 10 cases (9.8 %) were methylated in the MGMT gene, and 13 cases (12.7 %) were methylated in the RASSF1A gene (Fig. 1a-e) . No association was found among CHFR, MLH1, MGMT, and RASSF1A methylation with gender, age, tumor size, degree of differentiation, lymph node metastasis, and TNM stage ( Table 2 ). In 41 . In docetaxel-treated gastric cancer patients, overall survival was longer in the CHFR methylated group than in the CHFR unmethylated group (log-rank, p = 0.036; Fig. 2a ). In oxaliplatin-treated gastric cancer patients, overall survival was longer in the MLH1 unmethylated group than in the MLH1 methylated group (logrank, p = 0.046; Fig. 2b ).
Resistance to docetaxel treatment was found in CHFR unmethylated patients by the Cox proportional hazards model (HR 0.243, 95 % CI, 0.069-0.859, p = 0.028; Table 3 ), and resistance to oxaliplatin treatment was found in MLH1 methylated patients (HR 2.988, 95 % CI, 1.064-8.394, p = 0.038; Table 4 ).
In the oxaliplatin-treated group, there was no significant difference in overall survival between the CHFR methylated group and unmethylated group (p [ 0.05; Fig. 3a) . In the docetaxel-treated group, there was no statistical difference in overall survival between the MLH1 methylation group and the unmethylated group (p [ 0.05; Fig. 3b ). These results further suggest that CHFR methylation is a docetaxel-sensitive marker, and that MLH1 methylation is a oxaliplatin-resistant marker in gastric cancer.
Discussion
Hypermethylation of DNA repair genes is a frequent event in the carcinogenesis of gastric cancer. It is reasonable to explore the possibility of DNA methylation serving as prognostic and chemo-sensitive markers in gastric cancer. In 102 cases of primary gastric cancer, no FANCF was methylated; 34.4 % of CHFR was methylated, 21.6 % of MLH1 was methylated, 9.8 % of MGMT was methylated, and 12.7 % of RASSFA1 was methylated. Further analysis was only focused on CHFR and MLH1 because of the limited number of methylation cases.
Cell-cycle checkpoint dysfunction is often associated with sensitivity of chemotherapeutic agents [14, 15] , but mutation of mitotic checkpoint genes is rare in gastric cancer [16, 17] . Satoh et al. [3] found that CHFR is frequently methylated in gastric cancers, and other mitotic checkpoint genes (BUB1, BUB1B, BUB3, MAD2L1, MAD2L2, CENP-E, and EB1) are not inactivated. Further studies indicated that CHFR methylation is a sensitive molecular marker of microtubule inhibitors (docetaxel and paclitaxel) in gastric cancer cells. However, the relationship of CHFR methylation status and responsiveness to microtubule inhibitors in primary gastric cancer remains unclear. In our study, the methylation rate of CHFR gene was similar to previous reports in gastric cancer [18] [19] [20] . Resistance to docetaxel treatment was found in CHFR unmethylated patients by the Cox proportional hazards model (HR 0.243, 95 % CI, 0.069-0.859, p = 0.028; Table 3 ), and the overall survival was longer in the CHFR methylated group than in the CHFR unmethylated group in docetaxel-treated gastric cancer patients (log-rank, p = 0.036; Fig. 2a) . The results suggest that CHFR methylation is a sensitive marker for docetaxel in gastric cancer patients.
MLH1 is a major mismatch repair gene that has a role in maintaining the stability of the genome. Compared with colorectal cancer, mutations of DNA mismatch repair (hMLH1) are rare, despite the finding of high-frequency Fig. 2 Association of gene methylation and overall survival in gastric cancer patients. Kaplan-Meier survival curves were constructed according to the presence of gene methylation in gastric cancer. a In the docetaxel-treated group, overall survival is longer in the CHFR methylated group than in the CHFR unmethylated group. b In the oxaliplatin-treated group, overall survival is longer in the MLH1 unmethylated group than in the MLH1 methylated group microsatellite instability (MSI) in gastric cancer [21, 22] . MSI is reported to be mainly caused by hypermethylation of the MLH1 promoter [23] [24] [25] . Our data demonstrated that MLH1 was methylated in 21.6 % of Chinese primary gastric cancer cases. The methylation rate is similar to other reports [26, 27] . DNA mismatch repair plays a critical role in maintaining genomic integrity. Loss of DNA mismatch repair occurs in many types of tumors. The ability of mismatch repair proteins to correct DNA mismatches that occur during DNA replication, repair, and recombination was considered to be the major mechanism for maintaining genomic stability, but increasing evidence supports the suggestion that the mismatch repair system also contributes to genomic stability by stimulating DNA damage-induced apoptosis as part of the cytotoxic response to chemical agents [28] . It was reported that loss of MLH1 expression results in resistance to both cisplatin and carboplatin in a colorectal cancer cell line [29] . In an ovarian tumor cell line, development of cisplatin resistance is associated with MLH1 promoter hypermethylation [30] . Previous studies in breast and ovarian cancer have shown that MLH1 methylation significantly correlates with poor survival [31, 32] . There is no report about MLH1 methylation status and oxaliplatin sensitivity in gastric cancer. Resistance to oxaliplatin treatment was found in MLH1 methylated gastric cancer patients in our study (HR 2.988, 95 % CI, 1.064-8.394, p = 0.038; Table 4 ), and the overall survival was longer in the MLH1 unmethylated group compared with the MLH1 methylated group in oxaliplatin-treated gastric cancer patients (log-rank, p = 0.046; Fig. 2b ). However, there is no significant difference of overall survival between the CHFR methylation group and unmethylated group in the oxaliplatin-treated group, and no statistical difference of overall survival between the MLH1 methylation group and unmethylated group in the docetaxel-treated group in gastric cancer. These results suggest that MLH1 methylation may serve as an oxaliplatin resistance marker in gastric cancer. Some have tried to find methylation changes induced by chemotherapeutic reagents, but no strong evidence was found [33] [34] [35] .
In conclusion, CHFR is frequently methylated in human gastric cancer, and CHFR methylation may serve as a marker of docetaxel sensitivity. MLH1 methylation was related to oxaliplatin-resistant gastric cancer patients. Fig. 3 Association of gene methylation and overall survival in gastric cancer patients. Kaplan-Meier survival curves were constructed according to the presence of gene methylation in gastric cancer. a In the oxaliplatin-treated group, there is no significant difference in overall survival between the CHFR methylated group and the unmethylated group. b In the docetaxel-treated group, there is no statistical difference in overall survival between the MLH1 methylation group and the unmethylated group
